TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance

Bulletin Express09-02 19:23

TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share capital during the month.

Authorised and Issued Capital • Total authorised share capital stood at RMB 407.92 million, split between 312.69 million H-shares and 95.23 million unlisted ordinary shares, all at a par value of RMB 1.00 each. • Issued H-shares remained flat at 312.69 million, comprising 311.97 million shares in circulation and 0.72 million treasury shares. No new shares were issued, cancelled, or repurchased in August.

Public Float Status • The company confirmed compliance with the Hong Kong Main Board’s minimum 25 % public-float requirement as at month-end.

Equity Incentive Portfolio • The 2026 H Share Award Scheme held 2.44 million outstanding share options, unchanged from July. These options permit the future issuance of up to 35.53 million shares. • Separately, 2.82 million shares remain available for grant under the scheme’s share-award component, with no issuances or treasury transfers recorded during the month.

Overall, TransThera Sciences concluded August 2026 with an unchanged capital structure and affirmed regulatory compliance, providing continuity and stability in its equity profile.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115766616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-02 19:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115766616","market":"hk","top_or_hot":-1,"title":"TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance","media":"Bulletin Express","content":"<p>TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share capital during the month.</p>\n<p>Authorised and Issued Capital  \n• Total authorised share capital stood at RMB 407.92 million, split between 312.69 million H-shares and 95.23 million unlisted ordinary shares, all at a par value of RMB 1.00 each.  \n• Issued H-shares remained flat at 312.69 million, comprising 311.97 million shares in circulation and 0.72 million treasury shares. No new shares were issued, cancelled, or repurchased in August.</p>\n<p>Public Float Status  \n• The company confirmed compliance with the Hong Kong Main Board’s minimum 25 % public-float requirement as at month-end.</p>\n<p>Equity Incentive Portfolio  \n• The 2026 H Share Award Scheme held 2.44 million outstanding share options, unchanged from July. These options permit the future issuance of up to 35.53 million shares.  \n• Separately, 2.82 million shares remain available for grant under the scheme’s share-award component, with no issuances or treasury transfers recorded during the month.</p>\n<p>Overall, TransThera Sciences concluded August 2026 with an unchanged capital structure and affirmed regulatory compliance, providing continuity and stability in its equity profile.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransThera Sciences Posts Steady August 2026 Share Capital; Confirms Public Float Compliance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-09-02 19:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share capital during the month.</p>\n<p>Authorised and Issued Capital  \n• Total authorised share capital stood at RMB 407.92 million, split between 312.69 million H-shares and 95.23 million unlisted ordinary shares, all at a par value of RMB 1.00 each.  \n• Issued H-shares remained flat at 312.69 million, comprising 311.97 million shares in circulation and 0.72 million treasury shares. No new shares were issued, cancelled, or repurchased in August.</p>\n<p>Public Float Status  \n• The company confirmed compliance with the Hong Kong Main Board’s minimum 25 % public-float requirement as at month-end.</p>\n<p>Equity Incentive Portfolio  \n• The 2026 H Share Award Scheme held 2.44 million outstanding share options, unchanged from July. These options permit the future issuance of up to 35.53 million shares.  \n• Separately, 2.82 million shares remain available for grant under the scheme’s share-award component, with no issuances or treasury transfers recorded during the month.</p>\n<p>Overall, TransThera Sciences concluded August 2026 with an unchanged capital structure and affirmed regulatory compliance, providing continuity and stability in its equity profile.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02617","symbol_name":"药捷安康-B","start_time":0,"source_url":"","article_id":"1115766616","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115766616","pubTimestamp":1788348190,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02617":"药捷安康-B"},"translate_title":"TransThera Sciences 2026 年 8 月股本保持稳定；确认公众持股量合规性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02617":1},"content_text":"TransThera Sciences (Nanjing), Inc. (TRANSTHERA-B) has released its Monthly Return for Equity Issuer for the period ended 31 August 2026, showing no changes in either authorised or issued share capital during the month.\nAuthorised and Issued Capital  \n• Total authorised share capital stood at RMB 407.92 million, split between 312.69 million H-shares and 95.23 million unlisted ordinary shares, all at a par value of RMB 1.00 each.  \n• Issued H-shares remained flat at 312.69 million, comprising 311.97 million shares in circulation and 0.72 million treasury shares. No new shares were issued, cancelled, or repurchased in August.\nPublic Float Status  \n• The company confirmed compliance with the Hong Kong Main Board’s minimum 25 % public-float requirement as at month-end.\nEquity Incentive Portfolio  \n• The 2026 H Share Award Scheme held 2.44 million outstanding share options, unchanged from July. These options permit the future issuance of up to 35.53 million shares.  \n• Separately, 2.82 million shares remain available for grant under the scheme’s share-award component, with no issuances or treasury transfers recorded during the month.\nOverall, TransThera Sciences concluded August 2026 with an unchanged capital structure and affirmed regulatory compliance, providing continuity and stability in its equity profile.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115766616","isCrawlerRequest":true}